Download presentation
Presentation is loading. Please wait.
Published byShawn McGee Modified over 9 years ago
1
Cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries Ament A, Baltussen R, Duru G, Rigaud-Bully C, De Graeve D, et al, Journal of infectious diseases, Clinical Infectious Diseases, vol 31, nr 2, pp 444-50
2
Is vaccination a valuable preventive strategy? Pneumococcal Pneumonia is a serious threat to our health Treatment of Pneumococcal pneumonia is costly This is especially true in the elderly Vaccination can eliminate part of the clinical and economic consequences of pneumococcal disease But it generates costs as well (vaccine, administration, side-effects…) Analyse the cost-effectiveness of vaccination
3
Restriction to invasive disease – Analysis in five countries Much better evidence of clinical protection of the vaccine against invasive disease Information on the cost-effectiveness of vaccination in preventing invasive disease could provide strong support for public policies to provide strong support for public policies to vaccinate older individuals Belgium France, Scotland, Spain and Sweden; same methodology, different data
4
Characteristics of the evaluation Alternatives compared: vaccination versus treatment of persons 64+ years Measures of costs and effects Costs (C): direct medical costs for society in € 1995 Effects (E): number of qualys gained CE-ratio: C (Vaccination) - C (Treatment ) E (Vaccination) - E (Treatment)
5
Country-specific, age specific mortality rates Year 1 …year five
13
BelgiumFranceScotlandSpainSweden Base case † 25,907 ‡ 19,18214,89210,51132,675 Without influenza vaccination43,10637,88623,42220,01357,314 Incidence of disease (cases per 100,000 65 years) 30 / 100,00029,59315,21713,64523,77431,123 40 / 100,00021,00310,6339,97517,10121,821 50 / 100,00015,8497,8837,77313,09716,240 Mortality (%) 2019,79619,90423,1357,34215,024 3013,19713,26915,4234,89510,016 409,8989,95111,5663,6717,512 Results of the sensitivity analyses
14
BelgiumFranceScotlandSpainSweden Base case † 25,907 ‡ 19,18214,89210,51132,675 Vaccine price current price – 3.00 ecus21,67815,17412,1107,77023,875 current price + 3.00 ecus30,13623,19017,67313,25241,474 Vaccination effectiveness § best case17,32812,47310,1276,62220,991 worst case72,86853,28542,05537,276104,209 No quality-of-life adjustment16,30711,8879,2336,44420,017 Discount rate, 0%18,56513,76411,2587,41923,713 Discount rate, 5%31,22023,10917,51112,74739,111 Results of the sensitivity analyses
15
Conclusions The results support recent recommendations to vaccinate people aged 65 years and older with Pneumococcal P.S. Vaccine Even when only considering invasive disease, this strategy is acceptably to moderately cost- effective (less so for the very old) Very reliable data on incidence and mortality of S. pneumoniae would be good to convince the sceptics
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.